REFERENCES
1. Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.A., Dedov I.I. Epidemiology of diabetes mellitus in the Russian Federation: what has changed over the past decade? Terapevticheskiy arkhiv [Therapeutic Archive]. 2019; 91 (10): 4–13. DOI: https://doi.org/10.26442/00403660.2019.10.000364 (in Russian)
2. Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.A. Diabetes mellitus in the Russian Federation: prevalence, morbidity, mortality, parameters of carbohydrate metabolism and the structure of glucose-lowering therapy according to the federal diabetes register, status 2017. Sakharniy diabet [Diabetes Mellitus]. 2018; 21 (3): 144–59. DOI: https://doi.org/10.14341/DM9686 (in Russian)
3. Kaiser A.B., Zhang N., Pluijm W.V.D. Global prevalence of type 2 diabetes over the next ten years (2018–2028). Diabetes. 2018; 67 (suppl 1): 202. DOI: https://doi.org/10.2337/db18–202-lb
4. Dedov I.I., Kontsevaya A.V., Shestakova M.V., Belousov Y.B., Balanova J.A., Khudyakov M.B., et al. Economic evaluation of type 2 diabetes mellitus burden and its main cardiovascular complications in the Russian Federation. Sakharniy diabet [Diabetes Mellitus]. 2016; 19 (6): 518–27. DOI: https://doi.org/10.14341/DM8153 (in Russian)
5. Hicks C.W., Selvin E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr Diabetes Rep. 2019; 19 (10): 86. DOI: https://doi.org/10.1007/s11892–019–1212–8
6. Pop-Busui R., Boulton A.J.M., Feldman E.L., Bril V., Freeman R., Malik R.A., et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017; 40 (1): 136–54. DOI: https://doi.org/10.2337/dc16–2042
7. Fowler M.J. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2011; 29: 116–22. DOI: https://doi.org/10.2337/ diaclin.29.3.116
8. American Diabetes Association. Microvascular complications and foot care: standards of medical care in diabetes — 2020. Diabetes Care. 2020; 43 (suppl 1): 135–51. DOI: https://doi.org/10.2337/dc20-S 011
9. Kempler P. Review. Autonomic neuropathy: a marker of cardiovascular risk. Br J Diabetes Vasc Dis. 2003; 3: 84–90. DOI: https://doi.org/10.1177/14746514030030020201
10. Maser R.E., Mitchell B.D., Vinik A.I., Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care. 2003; 26: 1895–901. DOI: https://doi.org/10.2337/diacare.26.6.1895
11. Vinik A.I., Maser R.E., Mitchell B.D., Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003; 26: 1553–79. DOI: https://doi.org/10.2337/diacare.26.5.1553
12. Pop-Busui R., Evans G.W., Gerstein H.C., et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2010; 33: 1578–84. DOI. https://doi.org/10.2337/dc10–0125
13. Ziegler D., Gries F.A., Muhlen H., et al. Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes center. The DiaCAN Multicenter Study Group. Diabetes Metab. 1993; 19: 143–51.
14. Mamedova I.N., Ametov A.S. Berlition® in the treatment of cardiovascular disorders in diabetic autonomic neuropathy in patients with type 2 diabetes mellitus. Nervnye bolezni [Nervous Diseases]. 2004; (1): 39–42. (in Russian)
15. Jaiswal M., Divers J., et al. Cardiovascular autonomic neuropathy in adolescents and young adults with type 1 and type 2 diabetes: the SEARCH for Diabetes in Youth Cohort Study. Pediatr Diabetes. 2018; 19 (4): 680–9. DOI: https://doi.org/10.1111/pedi.12633
16. Koivikko M.L., Tulppo M.P., Kiviniemi A.M., et al. Autonomic cardiac regulation during spontaneous nocturnal hypoglycemia in patients with type 1 diabetes. Diabetes Care. 2012; 35 (7): 1585–90. DOI: https://doi.org/10.2337/dc11–2120
17. Ziegler D., Buchholz S., Sohr C., Nourooz-Zadeh J., Roden M. Oxidative stress predicts progression of peripheral and cardiac autonomic nerve dysfunction over 6 years in diabetic patients. Acta Diabetol. 2015; 52 (1): 65–72. DOI: https://doi.org/10.1007/s00592–014–0601–3
18. Jaiswal M., Fingerlin T.E., Urbina E.M., et al. Impact of glycemic control on heart rate variability in youth with type 1 diabetes: the SEARCH CVD study. Diabetes Technol Ther. 2013; 15 (12): 977–83. DOI: https://doi.org/10.1089/dia.2013.0147
19. Shah M.S., Brownlee M. Molecular and cellular mechanisms of cardiovascular disorders in diabetes. Circ Res. 2016; 118 (11): 1808–29. DOI: https://doi.org/10.1161/circresaha.116.306923
20. Giacco F., Brownlee M., Schmidt A.M. Oxidative stress and diabetic complications. Circ Res. 2010; 107: 1058–70. DOI: https://doi.org/10.1161/circresaha.110.223545
21. Creager M.A., Luscher T.F., Cosentino F., Beckman J.A. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003; 108: 1527–32. DOI: https://doi.org/10.1161/01.cir.0000091257.27563.32
22. Pavy-Le Traon A., Fontaine S., Tap G., Guidolin B., Senard J.M., Hanaire H. Cardiovascular autonomic neuropathy and other complications in type 1 diabetes. Clin Auton Res. 2010; 20: 153–60. DOI: https://doi.org/10.1007/s10286–010–0062-x
23. Rhee S.Y., Kim Y.S. the role of advanced glycation end products in diabetic vascular complications. Diabetes Metab J. 2018; 42 (3): 188–95. DOI: https://doi.org/10.4093/dmj.2017.0105
24. Yagihashi S., Mizukami H., Sugimoto K. Mechanism of diabetic neuropathy: where are we now and where to go? J Diabetes Investig. 2011; 2 (1): 18–32. DOI: https://doi.org/10.1111/j.2040–1124.2010.00070.x
25. Callaghan B.C., Little A.A., Feldman E.L., Hughes R.A. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012; 6: CD 007543. DOI: https://doi.org/10.1002/14651858.CD 007543.pub2
26. Ang L., Jaiswal M., Martin C., Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diabetes Rep. 2014; 14: 528. DOI: https://doi.org/10.1007/s11892–014–0528–7
27. Martin C.L., Albers J.W., Pop-Busui R.; DCCT/EDIC Research Group. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014; 37: 31–8. DOI: https://doi.org/10.2337/dc13–2114
28. Jaiswal M., McKeon K., Comment N., et al. Association between impaired cardiovascular autonomic function and hypoglycemia in patients with type 1 diabetes. Diabetes Care. 2014; 37 (9): 2616–21. DOI: https://doi.org/10.2337/dc14–0445
29. Ametov A.S., Kosyan A.A. Role and place of disturbed redox balance in the development of diabetic neuropathy and antioxidant effects of alpha-lipoic acid. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2020; 9 (2): 70–9. DOI: https://doi.org/10.33029 / 2304–9529–2020–9–2–70–79 (in Russian)
30. Ibrahim A. International Diabetes Federation. Clinical Practice Recommendation on the Diabetic Foot — 2017: a guide for health care professionals. Diabetes Res Clin Pract. 2017; 127: 285–7. DOI: https://doi.org/10.1016/j.diabres.2017.04.013
31. Pizova N.V. The main forms of diabetic neuropathies. Meditsinskiy konsul’tant [Medical Consultant]. 2018; 20 (4): 36–42. DOI: https://doi.org/10.26442/2075–1753_2018.4.36–42 (in Russian)
32. Pigarova E.A., Petrushkina A.A., Morozova E.V. Therapeutic potential of alpha lipoic acid. Effektivnaya farmakoterapiya [Effective Pharmacotherapy]. 2019; 15 (12): 40–5. DOI: https://doi.org/10.33978/23073586–2019–15–12–40–45 (in Russian)
33. Ziegler D., Nowak H., Kempler P., et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alphalipoic acid: a meta-analysis. Diabet Med. 2004; 21 (2): 114–21. DOI: https://doi.org/10.1111/j.14645491.2004.01109.x
34. Ziegler D., Ametov A., Barinov A., et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 trial. Diabetes Care. 2006; 29 (11): 2365–70. DOI: https://doi.org/10.2337/dc06–1216
35. P’yanykh O.P., Kosyan A.A., Garieva M.A. Complex therapy of diabetic polyneuropathy taking into account endothelial dysfunction in patients with type 2 diabetes mellitus. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2020; 9 (2): 31–9. DOI: https://doi.org/10.33029/2304–9529–2020–9–2–31–39 (in Russian)
36. Ametov A.S., Kosyan A.A., Pashkova E. Yu. Influence of hyperhomocysteinemia on the level of antioxidant enzymes in the blood and on the severity of diabetic neuropathy in patients with type 2 diabetes mellitus. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2019; 8 (2): 9–16. (in Russian)
37. Zhuravleva L.V., Lopina N.A. Analysis of the effectiveness of the use of alpha-lipoic acid in patients with very high cardiovascular risk. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2019; 8 (1): 31–40. (in Russian)
38. Ziegler D., Schatz H., Conrad F., Gries F.A., Ulrich H., Reichel G. Effects of treatment with the antioxidant α-lipoic acid on cardiac autonomic neuropathy in NIDDM patients: a 4-month randomized controlled multicenter trial (DEKAN study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care. 1997; 20 (3): 369–73. DOI: https://doi.org/10.2337/diacare.20.3.369
39. Ziegler D., Low P.A., Freeman R., Tritschler H., Vinik A.I. Predictors of improvement and progression of diabetic polyneuropathy following treatment with α-lipoic acid for 4 years in the NATHAN 1 trial. J Diabetes Complications. 2016; 30 (2): 350–6. DOI: https://doi.org/10.1016/j.jdiacomp.2015.10.018